- Home
- ABUS vs GHRS Comparison
ABUS vs GHRS Comparison
Compare ABUS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- GHRS
- Stock Information
- Founded
- ABUS 2005
- GHRS 2018
- Country
- ABUS United States
- GHRS Ireland
- Employees
- ABUS N/A
- GHRS N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- ABUS Health Care
- GHRS Health Care
- Exchange
- ABUS Nasdaq
- GHRS Nasdaq
- Market Cap
- ABUS 711.2M
- GHRS 811.3M
- IPO Year
- ABUS N/A
- GHRS 2021
- Fundamental
- Price
- ABUS $4.20
- GHRS $14.09
- Analyst Decision
- ABUS Strong Buy
- GHRS Strong Buy
- Analyst Count
- ABUS 3
- GHRS 8
- Target Price
- ABUS $5.67
- GHRS $30.63
- AVG Volume (30 Days)
- ABUS 1.0M
- GHRS 207.5K
- Earning Date
- ABUS 11-05-2025
- GHRS 08-07-2025
- Dividend Yield
- ABUS N/A
- GHRS N/A
- EPS Growth
- ABUS N/A
- GHRS N/A
- EPS
- ABUS N/A
- GHRS N/A
- Revenue
- ABUS $15,416,000.00
- GHRS N/A
- Revenue This Year
- ABUS $138.02
- GHRS N/A
- Revenue Next Year
- ABUS N/A
- GHRS N/A
- P/E Ratio
- ABUS N/A
- GHRS N/A
- Revenue Growth
- ABUS 53.23
- GHRS N/A
- 52 Week Low
- ABUS $2.71
- GHRS $6.00
- 52 Week High
- ABUS $4.73
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- ABUS 84.85
- GHRS 56.97
- Support Level
- ABUS $3.60
- GHRS $13.71
- Resistance Level
- ABUS $4.10
- GHRS $14.42
- Average True Range (ATR)
- ABUS 0.17
- GHRS 0.65
- MACD
- ABUS 0.06
- GHRS 0.19
- Stochastic Oscillator
- ABUS 83.33
- GHRS 77.68
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.